CTAG2 and cancer: Autologous T cells collected from three cancer patients were modified using Cas9 RNPs targeting TRAC, TRBC, and PDCD1 genes and further engineered with a lentivirus carrying an HLA‐A2*0201‐restricted TCR specific to cancer antigens NY‐ESO1 and LAGE‐1 to generate engineered T cells, called NYCE.